• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

EU antitrust officials charge Teva in ‘pay-for-delay’ deal

July 17, 2017 By Sarah Faulkner

Teva PharmaceuticalAntitrust regulators in the European Union charged Teva Pharmaceuticals (NYSE:TEVA) today, accusing the company of arranging an illegal deal with Cephalon to delay the sale of a cheap generic version to Cephalon’s sleep disorder drug, modafinil.

The EU competition officials have unleashed a series of fines against an array of companies in recent years over similar deals, including U.S. giant Johnson & Johnson (NYSE:JNJ).

The ‘pay-for-delay’ deals cost European consumers billions of euros, according to the antitrust regulators.

Teva arranged a deal with Cephalon to settle a lawsuit regarding alleged infringement of Cephalon’s patents for modafinial. Teva, the world’s largest generic drugmaker, later acquired Cephalon in 2011.

The EU Commission said the arrangement may have hiked the price of modafinil for European consumers.

“The patent settlement agreement between Cephalon and Teva may have caused substantial harm to EU patients and health service budgets,” the EU competition enforcer said in a statement, according to Reuters.

But the generic drugmaker pushed back against the group’s analysis.

“We do not believe that Cephalon and Teva entered into any anti-competitive behaviour,” the company reportedly said.

Teva could be fined up to 10% of its global turnover if it is found guilty of breaking EU antitrust regulations.

Material from Reuters was used in this report.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, Legal News, Pharmaceuticals, Wall Street Beat Tagged With: cephalon, johnsonandjohnson, Teva Pharmaceuticals

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS